Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Defective B cell tolerance in SLE lymph nodes underpins VH<sub>4-34</sub> "clonal damnation" and PD-1<sup>+</sup>TOX<sup>+</sup> autoreactive B cells expansion.

medRxiv : the preprint server for health sciences·2026

Same author

Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment response.

bioRxiv : the preprint server for biology·2026

Same author

Gut microbial IgA coating in infants with traditional farming lifestyle and urban infants with allergic outcomes.

Frontiers in immunology·2026

Same author

Update on allergen immunotherapy for asthma.

Current opinion in pulmonary medicine·2026

Same author

Farm exposure in infancy is associated with elevated systemic IgG<sub>4</sub>, mucosal IgA responses, and lower incidence of food allergy.

Science translational medicine·2025

Same author

Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

A perspective on B-cell-targeting therapy for SLE.

R John Looney¹, Jennifer Anolik, Inaki Sanz

¹Division of Allergy Immunology Rheumatology, Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Room G-6427C, Rochester, NY, 14642, USA. John_Looney@URMC.Rochester.Edu

Modern Rheumatology

|August 12, 2009

Summary

This summary is machine-generated.

Despite recent setbacks in clinical trials, B-cell-targeting therapies show promise for systemic lupus erythematosus (SLE). Further research is needed to understand trial failures and optimize future treatment strategies for lupus patients.

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Related Experiment Videos

Last Updated: Jun 21, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

Immunology
Rheumatology
Clinical Trials

Background:

Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
B cells play a critical role in SLE pathogenesis, supported by murine models and open-label studies.
Several novel B-cell-targeting agents have been investigated in large controlled trials for SLE.

Purpose of the Study:

To review the current status of B-cell-targeting therapies for human lupus.
To analyze the reasons for the failure of recent controlled trials in demonstrating efficacy.
To discuss future directions for developing B-cell-targeting treatments for SLE.

Main Methods:

Review of recent large controlled trials of B-cell-targeting agents in SLE.
Analysis of biological and clinical effects of tested drugs, including rituximab, belimumab, epratuzumab, and TACI-Ig.
Discussion of potential flaws in trial design and execution.

Main Results:

No recent large controlled trials for SLE met their primary outcome.
Significant knowledge has been gained regarding lupus clinical trial conduct and drug effects.
The efficacy of B-cell-targeting therapies in controlled SLE trials remains uncertain despite preclinical and open-label data.

Conclusions:

Recent controlled trials of B-cell-targeting therapies for SLE have not met primary endpoints.
The reasons for trial failures require careful examination, considering trial design and the translation of preclinical findings.
Future development of B-cell-targeting therapies for SLE necessitates a re-evaluation of strategies and a deeper understanding of disease mechanisms.